Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.71 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | RET | P07949 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.52 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.52 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809158 | 0.93 | EGFR (0.67) | EGFRKDRRETERBB2ERBB4 | |
| SCHEMBL17836949 | 0.92 | EGFR (0.70) | EGFRKDRRETLCKAURKB | |
| SCHEMBL5240218 | 0.88 | EGFR (0.79) | EGFRKDRRETLCKAURKB | |
| SCHEMBL4230302 | 0.87 | EGFR (0.67) | EGFRKDRERBB2AURKBAURKA | |
| SCHEMBL1467608 | 0.85 | EGFR (0.69) | EGFRKDRRETERBB2ERBB4 | |
| SCHEMBL30891782 | 0.85 | EGFR (0.83) | EGFRKDRRETLCKERBB2 | |
| Hydrochloric Acid SCHEMBL7453718 | 0.85 | EGFR (0.68) | EGFRKDRRETLCKERBB2 | |
| SCHEMBL6686765 | 0.83 | EGFR (0.79) | EGFRKDRRETLCKERBB2 | |
| SCHEMBL7225895 | 0.83 | EGFR (0.49) | EGFRLCKIRAK4 | |
| SCHEMBL4224921 | 0.82 | EGFR (0.48) | EGFRKDRLCKERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | EGFR 1731/4885KDR 2523/4885RET 1204/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | EGFR 1789/4885KDR 2393/4885RET 1283/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | EGFR 1503/4885KDR 2189/4885RET 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.